| Literature DB >> 9872930 |
I Blasko1, F Marx, E Steiner, T Hartmann, B Grubeck-Loebenstein.
Abstract
The appearance of inflammatory markers associated with amyloid plaques indicates a state of chronic inflammation in Alzheimer's disease (AD). Multiple epidemiological studies also suggest that patients taking anti-inflammatory drugs have a decreased risk of developing AD. Here we present evidence that inflammatory cytokines can alter the metabolism of the beta-amyloid precursor protein (betaAPP). We show that the combination of tumor necrosis factor alpha and interferon gamma triggers the production of beta-amyloid peptides and inhibits the secretion of soluble APPs by human neuronal and extraneuronal cells. The results demonstrate a new mechanism by which inflammatory components can exacerbate the fundamental pathology in AD.Entities:
Mesh:
Substances:
Year: 1999 PMID: 9872930 DOI: 10.1096/fasebj.13.1.63
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191